The Listing of the Claims:

1. (currently amended) A compound for modulating c-Kit activity according to Formula I,

I

or a pharmaceutically acceptable salt, thereof, wherein,

ring A is:

(R ¹) ₀₋₄	(R ¹) ₀₋₃ (R ¹)	$(R^1)_{0-3}$
N \ (R ¹) ₀₋₁	$ \begin{pmatrix} Z & \frac{1}{\parallel} \\ N & N & N \end{pmatrix} $ $ (R^1)_{0-2} $	N Z (R ¹) ₀₋₁
(R ¹) ₀₋₁	$N = \{ \frac{Z}{\frac{1}{ I }} \}$ $(R^1)_{0-1}$	Z N
(R ¹) ₀₋₄ Y	(R ¹) ₀₋₅ Z Z Y Y Y	(R ¹) ₀₋₅ Y
(R ¹) ₀₋₆ Z Y Y	(R ¹) ₀₋₆ Y Y Y	$(R^1)_{0-6} \xrightarrow{\gamma} \qquad \qquad \qquad \gamma \xrightarrow{\gamma} \qquad \qquad \gamma \xrightarrow{\gamma} \qquad \gamma \xrightarrow$

wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and - $N(R^7)$ -;

- each R^1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R¹, together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁰;

L¹ is a single bond;

ring B is phenyl a five to ten-membered aryl or a five to ten-membered heterocyclyl;

- each R^2 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R², together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁵;
- L^2 is selected from -N(H)N(H)C(=O)N(H)-, -CH₂N(H)C(=O)N(H)-, -CH₂OC(=O)N(H)-, and -XCH₂C(=O)N(H)-; wherein X is selected from -O-, -S(O)₀₋₂-, and -N(R⁷)-; and any C-H of L^2 is optionally C-R²⁰;

ring C is phenyl or pyridyl;

each R³ is independently selected from halogen, trihalomethyl, -CN,

-NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide,

wherein there exists at least one of R³ that is halogen or trihalomethyl;


- two adjacent of R³, together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R²⁵;
- R⁴ is selected from -H, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;
- two of R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkenyl, and optionally substituted C₁₋₆alkynyl;
- R^7 is selected from -H, optionally substituted C_{1-6} alkyl, $-SO_2N(R^4)R^4$, $-CO_2R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; and
- each of R^{10} , each of R^{15} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl,

optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

provided:

1) when both ring B and ring C are phenyl:

- a) and the compound comprises ring B-CH₂N(H)C(=O)N(H) ring C, then L¹ must be a single bond; R³ can not comprise a group of the formula -O(CH₂)₂₋₄-N-piperazine that is ortho to L²; and ring A cannot be a 5-methyl-[1,2,4] oxadiazol-3-yl radical, a 4H-[1,2,4] oxadiazol-5-one 3-yl radical, nor a 4' [2,2';6',2"]terpyridinyl radical;
- b) and L¹-is single bond, then L² cannot comprise -N(H)C(=O)C(=O)N(H) nor -N(H)C(=Q)C(H)CNC(=O) (where Q is S or O);
- e) and L¹ is other than single bond, then A cannot be quinolin-2-yl-L¹, quinolin-3-yl-L¹; or quinolin-4-yl-L¹;
- 2) when ring A is a fused aryl system, then L¹-must be a single bond;
- 3) when ring B is phenyl, ring C is a C₆₋₁₆carbocyclic, L¹ is a single bond, and the compound comprises ring B-OCH₂C(-O)N(H) then ring A cannot be a 2,5-dimethyl-1H-pyrrole-1-yl-radical;
- 4) ring A cannot be a pyrimidin 2 yl radical when L¹ is N(H) and ring B is phenyl;
- 5) when the compound comprises the formula,



where V is =C(H)- or =N-, and there is a nitrogen of L^2 bound directly to ring B, then A can not comprise a [1,2,4]-oxadiazol 3-yl radical; and

6) the compound is not one of: N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl-2-(1H-tetrazol-1-yl-2-{[3-(1H-tetrazol-1-yl-2-(1H-tetrazol-1-yl-2-yl-2-(1H-te

```
N-(3.4-dimethylphenyl)-2-([3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide,
yl)phenyl]oxy}acetamide, N-(2,3-dimethylphenyl)-2-[[3-(1H-tetrazol-1-
yl)phonyl]oxy]acetamide,
                               N (2,4-dimethylphenyl) 2-{[3-(1H-tetrazol-1-
                              N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-
yl)phenylloxy) acetamide,
                            N (3,5 dimethylphenyl) 2 [[3 (1H tetrazol-1-
yl)phenyl]oxy)acetamide,
yl)phenyl]oxy}acetamide, N-(2,6-dimethylphenyl)-2-[[3-(1H-tetrazol-1-
yl)phenylloxylacetamide, 2-{[3-(1H-tetrazol-1-yl)phenylloxy}-N-(2,4,6-
trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy]acetamide, N-(4-ethylphenyl)-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide, N-(2,6-diethylphenyl)-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide, N-[2-(ethyloxy)phenyl]-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy)acetamide, N-[2,4-bis(methyloxy)phenyl]-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-
yl)phenyl]oxy) acetamide,
                                N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-
vl)phenylloxy}acetamide.
                           N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-
yl)phenylloxy}acetamide,
                                    N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide,
                                    N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide,
                                    N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide,
                                   2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-
(trifluoromethyl)phenyl]acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-
(trifluoromethyl)phenyl]acetamide,
                                      methyl 4-[({[3-(1H-tetrazol-1-
                                       ethyl 4 [({[3 (1H-tetrazol-1-
yl)phenyl]oxy}acetyl)amino]benzoate,
yl)phenyl]oxy}acetyl)amino]benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl]
oxy|acetyl)amino|benzoic acid, N-[3 (methyloxy)phenyl]-2-[[3-(1H-tetrazol-1-
yl)phenyl]oxy}acetamide, N [4 (methyloxy)phenyl] 2 {[3 (1H tetrazol 1-
yl)phenyl]oxy}acetamide, N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1H-
tetrazol-1-yl)phenyl]oxy}acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-
```

{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} <u>acetamide</u> <u>or</u> <u>acet-amide</u>, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-aminophenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, and N-(4-acetylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

2-12. (cancelled)

- 13. (Currently Amended) The compound according to claim $\frac{10}{1}$, wherein there exists at least one of \mathbb{R}^3 that is trifluoromethyl.
- 14. (original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical *meta* to L^2 .
- 15. (currently amended) The compound according to <u>claim 1</u>, <u>claim 10</u>, wherein each of \mathbb{R}^3 is independently selected from halogen, trihalomethyl, $-O\mathbb{R}^4$, $-C(=O)\mathbb{R}^4$, and optionally substituted C_{1-6} alkyl.
- 16. (currently amended) A compound for modulating c-Kit activity according to the following Formula: H₃

$$(R^{26})_{0.4}$$
 H
 $(R^{30})_{1.5}$

П

or a pharmaceutically acceptable salt, thereof, wherein,

W is selected from the following:

$(R^{27})_{0.4}$	(R ²⁷) ₀₋₃	$(R^{27})_{0-3}$
$(R^{27})_{0-1}$	$Z = \frac{1}{\frac{1}{11}}$ $(R^{27})_{0-2}$	N-Z -N (R ²⁷) ₀₋₁
(R ²⁷) ₀₋₁	$(\mathbb{R}^{27})_{0-1}$	Z N
(R ²⁷) ₀₋₄ Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—Y—	(R ²⁷) ₀₋₅ Y Z Z Y Y Y	(R ²⁷) ₀₋₅ Y Y Y Z Z Z
(R ²⁷) ₀₋₆ Z Y Y Y Y	(R ²⁷) ₀₋₆ Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	$(R^{27})_{0-6} \xrightarrow{\dot{Y}} Y \xrightarrow{\dot{Y}} Y \xrightarrow{\dot{Y}} Y$

each of R^{27} independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁵⁵, -S(O)₀₋₂R⁵⁵, -SO₂N(R⁵⁵)R⁵⁵, -C(=O)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)R⁵⁵, -N(R⁵⁵)SO₂R⁵⁵, -N(R⁵⁵)C(O)R⁵⁵, -NCO₂R⁵⁵, -C(=O)R⁵⁵, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl C_{1-6} alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O) $_{0-2}$ -, and -N(R 7)-

E and G are each independently selected from -O-, -S(O)₀₋₂-, -C(R³¹)R³²-, and -N(R³³)-; J_1 and J_2 are each independently =C(H)- or =N-;

- R^{26} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{30} is independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trihalomethyl; or
- two adjacent of R²⁶ or two adjacent of R³⁰, together with the annular atoms to which they are attached, can form a five to six membered ring containing up to two heteroatoms and optionally substituted with up to three of R³⁵;
- R^{31} and R^{32} are each independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R^{40})R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R^{40})R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R^{40})R⁴⁰, -C(=NR⁵⁰)N(R^{40})R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R^{40})SO₂R⁴⁰, -N(R^{40})C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{33} is selected from -H, optionally substituted lower alkyl, $-SO_2N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)N(R^{40})R^{40}$, $-C(=NR^{50})N(R^{40})R^{40}$, $-C(=NR^{50})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{40} is selected from -H, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl,

and optionally substituted heterocyclyl C₁₋₆alkyl;

- two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^{50} is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted C₁₋₆alkenyl, and optionally substituted C₁₋₆alkynyl;
- R⁵⁵ is selected from -H, optionally substituted C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl; and
- two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.
- 17. (cancelled)
- 18. (currently amended) The compound according to claim $\frac{17}{16}$, wherein R^{30} is selected from halogen, trihalomethyl, $-OR^{40}$, $-N(R^{40})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trifluoromethyl.
- 19. (cancelled)
- 20. (cancelled)
- 21. (cancelled)
- 22. (cancelled)
- 23. (withdrawn from consideration, currently amended) The compound according to elaim 22, claim 16, wherein E is selected from -O-, -S(O)₀₋₂-, and -NH-; and G is -CH₂-.

- 24. (withdrawn from consideration, currently amended) The compound according to elaim 22, claim 16, wherein E is either -CH₂- or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (cancelled)
- 26. (cancelled)
- 27. (currently amended) The compound according to claim 1, selected from Table 3:

A compound selected from the following Table:

Table 3			
Entry	Name	Structure	
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ NH NI NI NI NI NI NI NI NI NI	
2	N-phenyl 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N-N N-N HN	
3	N (2-methylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. H ₃ C	

Table 3		
Entry	Name	Structure
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N = N CI
6	ethyl 2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate	N.N.N H S
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N CH3 CI
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N

	Table 3		
Entry	Name	Structure	
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N.	
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. CH3	
12	N-(4-morpholin-4-ylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N	
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N. N. P. P. F.	

Table 3		
Entry	Name	Structure
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N. O.N. H. F.
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	O N F F F F
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N N N N N N N N N N N N N N N N N N N
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH ₃ O N F F
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ H F F CI

	Table 3		
Entry	Name	Structure	
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N. CH3	
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	
21	N-[4-chloro-3 (trifluoromethyl)phenyl] 2- {[3-(2,5-dioxopyrrolidin-1- yl)phenyl]oxy)acetamide	DE LOS CONTRACTOR OF FEBRUARY	
22	(2E) N-[4-chloro-3- (trifluoromethyl)phenyl] 3-[3-(1H- tetrazol-1-yl)phenyl]prop-2-enamide	H F F CI	
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	NN HN FF	
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H ₃ C F F	

Table 3		
Entry	Name	Structure
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	S N H F F F F F F F F F F F F F F F F F F
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	H N N F F
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
29	methyl 1-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-1,2,3-triazole-4- carboxylate	CH ₃ O O CI

Table 3		
Entry	Name	Structure
30	1,1 dimethylethyl {4 [({[3 (1H tetrazol 1 yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	NN N N N N N N N N N N N N N N N N N N
31	1,1-dimethylethyl {4-[({[4-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	NN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N
32	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N-N O THOUSE CH,
- 33	N-{4-[(1-ethylpiperidin-3- yl)amino]phenyl}-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH3
34	N-(4-aminophenyl)-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N

Table 3		
Entry	Name	Structure
35	N {4 [(1 ethylpiperidin 4 yl)amino]phenyl} 2 {[4 (1H tetrazol 1 yl)phenyl]oxy}acetamide	H ₃ C N H
36	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ NH
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N CI F F
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CH ₃ O CH ₃
39	N 1,3-benzothiazol-2-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	ON NH NZN.

Table 3		
Entry	Name	Structure
40	N quinolin 8 yl-2-{[3 (1H tetrazol-l- yl)phenyl]oxy}acetamide	ON ON N.
41	N-(2,3 dihydro 1,4 benzodioxin 6 yl) 2- {[3 (1H-tetrazol-1- yl)phenyl]oxy}acetamide	ON ON N. N.
4 2	N-isoquinolin-5-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	O N-N'N
43	N-{3-[(phenylmethyl)oxy]phenyl}-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	O TENTO TENT
44	N [5 methyl 2 (methyloxy)phenyl] 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C NH N-N N

	Table 3		
Entry	Name	Structure	
45	N [2,5 bis(methyloxy)phonyl] 2 {[3 (1H-tetrazol 1-yl)phonyl]oxy}acetamide	H ₃ C.O.NH NO.N.N	
4 6	N-(6-fluoro-1,3-benzothiazol-2-yl)-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	F N N N N N N N N N N N N N N N N N N N	
47	methyl 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzoate	H ₃ C.OCO	
48	5-chloro-2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzamide	N N HN CI	
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	2 Z Z Z C C C C H ² C C C C H ² C C C C C C C C C C C C C C C C C C C	

	Table 3		
Entry	Name	Structure	
50	N-[2 (phenyloxy)phenyl] 2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	OHO N.	
51	N-[3-(aminosulfonyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	0.5.0 0.5.0	
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N. H. F.	
53	N-(4-{[(4- methylphenyl)sulfonyl]amino}phenyl)-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃	
54	N (5 phenyl-1H-pyrazol-3-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	O NO	

Table 3		
Entry	Name	Structure
55	N-1,3-benzothiazol-2-yl-2-{[4-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
56	N-quinolin-8-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-pyrrole-1- carboxylate	2
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	CI FF F
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	D H H L C I H

Table 3		
Entry	Name	Structure
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	N. N. P. P. F.
61	4-chloro N (2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}ethyl) 3- (trifluoromethyl)aniline	N-J CI F I'F
62	N [4-chloro-3-(trifluoromethyl)phenyl]-N- (2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}ethyl)formamide	D C C C C C C C C C C C C C C C C C C C
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	CI F F F
64	N [4 chloro 3 (trifluoromethyl)phenyl] 2- [(3 furan 3 ylphenyl)oxy]acetamide	O CI FF H F
65	(2E) N [4 fluoro 3 (trifluoromethyl)phenyl] 3 [3 (1H-tetrazol 1 yl)phenyl]prop 2 enamide	N=N O F

Table 3		
Entry	Name	Structure
66	N-[4-fluoro-3-(trifluoromethyl)phenyl]-3- [3-(1H-tetrazol-1-yl)phenyl]propanamide	H F F N N N N N N N N N N N N N N N N N
67	N [4-chloro 3 (trifluoromethyl)phenyl] 2- {[6-(1H-tetrazol-1-yl)pyrimidin-4- yl]oxy}acetamide	N H F F CI
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	H_3C CI F F F F
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	CI FFFF F
70	N [4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-2-ylphenyl)oxy]acetamide	CI FF H F

Table 3		
Entry	Name	Structure
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N. N. H. N. H. H. F.
72	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-dibenzo[b,d]furan-4- ylphenyl)oxy]acetamide	H F F CI
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N CI
74	N methyl N [4 (methyloxy)phenyl] 2 {[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	N CH ₃
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	NN CI FFF

Table 3		
Entry	Name	Structure
76	N-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ N°N O O CI
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N H F F F F F F F F F F F F F F F F F F
78	N [4 fluoro 3 (trifluoromethyl)phenyl] 2- [H P F F
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	F F F N N N N N N N N N N N N N N N N N
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	CI F F

Table 3		
Entry	Name	Structure
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N F F
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	N N F F F
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N N P F F F
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N. N. N. P. F.
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	O NH F F

Table 3		
Entry	Name	Structure
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	N. N
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	N. N. N. P.
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H ₃ C O N F F F
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	ON PER
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F CI F F F F

Table 3		
Entry	· Name	Structure
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F CI F F F F
92	N ({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3 (1H-tetrazol-1-yl)benzenesulfonamide	N Q Q Q CI N N N N F F
93	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- N-methyl-3-(1H-tetrazol-1- yl)benzenesulfonamide	N O O O CI N N N CH ₃ H F F
⁻ 94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	O NH F F
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₁ O N F F F F F F F F F F F F F F F F F F

	Table 3		
Entry	Name	Structure	
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₂ O N P F F	
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	ZH O TH O TH O	
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H ₃ C ² O N H F F F	
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N H F F F	
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	CI F F F	

Table 3		
Entry	Name	Structure
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (2,3,5,6-tetrafluoro-4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	E E E E E E E E E E E E E E E E E E E
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	O N F F
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	CO FF F
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N N N F F
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N N N N N N N N N N N N N N N N N N N

Table 3		
Entry	Name	Structure
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	Z-Z Z-Z Z-Z Z-Z Z-Z Z-Z Z-Z Z-Z
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C. O N N N N F F
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ² C, O N N N N N N N N N N N N N N N N N N
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C'O CI N H H F F
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C. _O N

Table 3		
Entry	Name	Structure
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C. _O N
112	1,1-dimethylethyl 2 {4 [(2 {[4 chloro 3- (trifluoromethyl)phenyl]amino} 2- oxoethyl)oxy]phenyl} 1H indole 1- carboxylate	ON THE F
113	N ({[4 chloro 3- (trifluoromethyl)phenyl]amino}carbonyl)- 4 (1H tetrazol 1 yl)benzenesulfonamide	0.0 0 F S N N F N N N N
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	P CI F F F

Table 3		
Entry	Name	Structure
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N CI F F F
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	CI F F F F
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	N. H. H. L.

Table 3		
Entry	Name	Structure
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON PLANE
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CI F F F
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O NH FFF
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	N N N F F
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	N N N N N N N N N N N N N N N N N N N

Table 3		
Entry	Name	Structure
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	HZ HZ LZ
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyrimidin-5-ylphenyl)methyl]urea	J. J. J. O. CH ³
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyridin-3-ylphenyl)methyl]urea	N N N O CH3
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	O N O CH3
130	(4-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	ON CH3

Table 3		
Entry	Name	Structure
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	PHO PH
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CI FFF
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyridin-3-ylphenyl)methyl]urea	N N O CH3
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyrimidin-5-ylphenyl)methyl]urea	N N O CH3
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N O CH3

	Table 3		
Entry	Name	Structure	
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N O'CH3	
137	N [4-chloro-3 (trifluoromethyl)phenyl] 2- methyl-2 (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	CH ₃ O CI N N N F F	
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	NH NH F F	
139	N-{[3-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N Q CI	
140	N {[4 (6 aminopyridin 3 yl)phenyl]methyl} N' [4 chloro 3 (trifluoromethyl)phenyl]urea	H ₂ N N F F	
141	N-{[3-(2-aminopyrimidin-5-yl)phenyl]methyl}-N' [4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N O CI	

Table 3		
Entry	Name	Structure
142	N-{[4-(2-aminopyrimidin-5-yl)phenyl]methyl}-N' [4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH ₃ NH F
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	ZH ZH C F F
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	O NH FFF
146	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (isoquinolin-7-yloxy)acetamide	H F F CI

Table 3		
Entry	Name	Structure
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	ZH Z
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	N N N N F F
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N N N CI F F F
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	N N N F F
151	methyl 3-amino 6 (3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2- carboxylate	CH ₃ O O O N N N N F F

Table 3		
Entry	Name	Structure
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	N N N N N N N N N N N N N N N N N N N
153	N {[3 (2 amino 5 methylpyridin 3 yl)phenyl]methyl} N' [4 chloro 3 (trifluoromethyl)phenyl]urea	CH ₃ O F NH ₂ H H F F
154	methyl 3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2- carboxylate	CHO N N F F
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	N = N O CI O CH3
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N N N N N N N N N N N N N N N N N N N

Table 3		
Entry	Name	Structure
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N H F F
158	N-{[3 (2 amino 5 chloropyridin 3 yl)phenyl]methyl} N'-[4 chloro 3 (trifluoromethyl)phenyl]urea	N NH ₂ O CI
159	N-{[4 (2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH ₂
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N
162	N [4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(pyrimidin-2- yloxy)phenyl]methyl}urea	CI NO H H FF

Table 3		
Entry	Name	Structure
163	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzamide	N N CI N N N FF
164	3-amino-6 (3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[2- (dimethylamino)ethyl]pyrazine-2- carboxamide	HN O HN O HN O N O N O N O N O N O N O N
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N N F F
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C·O
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N

Table 3		
Entry	Name	Structure
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	N N N F F F
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	N N CF3
170	N-{[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	P N N CF3
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N N N N N N F F
172	N-{[4-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N NH ₂
173	N-{[3-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	NH ₂ N N F F

	Table 3		
Entry	Name	Structure	
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C N F F F	
175	[3 (2 amino 5 fluoropyridin 3 yl)phenyl]methyl [4 chloro 3 (trifluoromethyl)phenyl]carbamate	P Q CI NH ₂ O N F F	
176	[3-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	NH ₂ ON F	
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	C F F F	
178	N-[4-chloro 3 (trifluoromethyl)phenyl] N'- ({3 [6 (hydroxymethyl)pyridin 3- yl]phenyl} methyl)urea	HO N CF3	
179	N-{[3-(6-acetylpyridin-3- yl)phenyl]methyl}-N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	H ₃ C N CF,	

Table 3		
Entry	Name	Structure
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	CN N Q CI N N CF3
181	1,1 dimethylethyl (3S) 3 ({[3 amino 6 (3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	$\begin{array}{c c} & & & \\ & & & &$
· 182	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	HN FF CI HN O HN O O
183	1,1 dimethylethyl (3S) 3 ({[3 amino 6 (4 {[({[4 chloro 3 {trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin 2-yl]carbonyl}amino)piperidine 1-carboxylate	CI NH

	Table 3		
Entry	Name	Structure	
184	3-amino 6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl) N-[(3S) piperidin-3-yl]pyrazine-2-carboxamide	CI NH	
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN P F F	
186	N-{[3 (2-amino 5-fluoropyridin 3-yl)phenyl]methyl}-N'-[4-chloro 3-(trifluoromethyl)phenyl]urea	NH ₂ N N F F	
187	[6 (1H tetrazol 1 yl)pyridin 2 yl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F	
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F	

	Table 3		
Entry	Name	Structure	
189	[3 (6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₂ N O N F F	
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	S CH ₃ CF ₃	
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C N	
192	[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F N NH ₂	
193	[4 (2-aminopyridin-3-yl)phenyl]methyl [4- ehloro-3- (trifluoromethyl)phenyl]carbamate	ON FE	
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI N F F F	

	Table 3	
Entry	Name	Structure
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN F F
196	[4 (6 amino 2 methylpyridin 3-yl)phenyl]methyl [4 chloro 3 (trifluoromethyl)phenyl]carbamate	H ₂ N CH ₃
197	[3-(1H-tetrazol-1-yl)phenyl]methyl-1,3- benzothiazol-2-ylcarbamate	N N N S
198	[3-(1H-tetrazol-1-yl)phenyl]methyl (5- bromopyridin-2-yl)carbamate	N N N N N N N N N N N N N N N N N N N
199	(3-pyridin-3-ylphenyl)methyl (3,5- dimethylphenyl)carbamate	CH ₃ ON CH ₃
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH ₃ O N CI

Table 3		
Entry	Name	Structure
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	Z-Z Z-Z Z-Z Z-Z F F
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro- 2-(methyloxy)phenyl]carbamate	CH ₃
203	(4-pyrimidin-5-ylphenyl)methyl (3,4- dimethylphenyl)carbamate	N CH ₃
204	(3-pyridin-3-ylphenyl)methyl (3,4- dimethylphenyl)carbamate	ON CH ₃
205	1,1 dimethylethyl 3 ({[3-amino 6 (3- {[({[4-chloro 3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin 2- yl]carbonyl}amino)piperidine 1- carboxylate	HN O HN O O

Table 3		
Entry	Name	Structure
206	1,1-dimethylethyl 3-({[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	NH N
207	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-piperidin-3- ylpyrazine-2-carboxamide	HN O HN O
208	3-amino-6 (4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl) N-piperidin-3-ylpyrazine-2-carboxamide	F F CI NH NN NH NN

Table 3		
Entry	Name	Structure
209	1,1 dimethylethyl 4 {[3 amino 6 (3 {[({[4 chloro 3 {trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin 2-yl]carbonyl}piperazine 1 carboxylate	CI F F F NH NH NH
210	1,1-dimethylethyl 4-{[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	F F F CI NH HN O
211	N ({3 [5 amino 6 (piperazin 1- ylcarbonyl)pyrazin 2 yl]phenyl}methyl) N' [4 chloro 3- (trifluoromethyl)phenyl]urea	H ₂ N N HN O

	Table 3		
Entry	Name	Structure	
212	N-({4-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	F F CI H H N O H N N N N N N N N N N N N N N N	
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N H CF ₃	
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF ₃	
215	[3-(2-piperazin-1-ylpyrimidin-5- yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	HN N CF3	

Table 3		
Entry	Name	Structure
216	[4-(2-piperazin-1-ylpyrimidin-5- yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CF ₃ CI HN O O
217	N-{[3-(2-chloropyridin-3- yl)phenyl]methyl}-N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	N CI O CF ₃
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH CF3
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N F CF ₃
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N N CF3

Table 3		
Entry	Name	Structure
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	N N N N N N N N N N N N N N N N N N N
222	[3-(1H-tetrazol-1-yl)phenyl]methyl [6- (trifluoromethyl)pyridin-2-yl]carbamate	N N F F
223	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- (trifluoromethyl)pyridin-2-yl]carbamate	N N F F F
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H ₃ C ^{-S} CI N N CF ₃
225	[3-(2,6-dimethylpyridin-3- yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C CF ₃

Table 3		
Entry	Name	Structure
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	Or CH ₃ O N CF ₃ CF ₃
227	2,3'-bipyridin-6-ylmethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N N O N F F F
228	(6-pyrimidin-5-ylpyridin-2-yl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CI F F F
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	N CF ₃
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	N N CF3

Table 3		
Entry	Name	Structure
231	[6 (1H tetrazol 1 yl)pyridin 2 yl]methyl [4 (trifluoromethyl)pyridin 2 yl]carbamate	N O N F F
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	HN N

- 28. (previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
- 29. (cancelled)
- 30. (withdrawn from consideration, currently amended) A method for modulating the *in-vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to <u>claim 1</u>. <u>claim 1</u> or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4 (phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}

acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4dimethylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N (3,5-dimethylphenyl) 2 {[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N (3, vl)phenylloxy) acetamide, N-(2,6 dimethyl-phenyl) 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} N-(2,4,6trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-[[3-(1H-tetrazol-1-yl) phenyl]oxy] acetamide, N (4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H tetrazol-1-yl)phenyl]oxy]acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy]-acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3dichlorophenyl) 2 {[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, N (4 chloro-3-methylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy acetamide, N (2 fluorophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy acetamide, N (4 fluorophenyl) 2-{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3 (1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}-N-[2 (trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, 3-[([3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid, N-[3 (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4chlorophenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} tetrazol-1-vl)phenylloxy} acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide.

31. (withdrawn from consideration) The method according to claim 30, wherein the kinase is c-Kit.

- 32. (withdrawn from consideration) The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.
- 33. (withdrawn from consideration, currently amended) A method of treating rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; artheroscrosis, myocardioinfarction, ischemia, stroke, restenosis; interbowel diseases, osteoarthritus, macular degeneration, or diabetic retinopathy, diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in claim 1 or a compound, or a pharmaceutical composition comprising said compound, selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethyl-phenyl)-2-{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl)-acetamide, N-(2-ethyl-phenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3 (1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[3 (ethyloxy)phenyl] 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy} acetamide, N-[2,4-bis(methyl-oxy)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)-phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy]acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3methylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy} acetamide, N (2 fluorophenyl)-2-{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N (4 fluorophenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy}-N [2 (trifluoro-methyl)phenyl] -- acetamide, -- 2-{[3 (1H tetrazol-1yl)phenyl]oxy] N-[3 (trifluoromethyl) phenyl] acetamide, methyl 4-[([[3-(1H tetrazol-1-

yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4 [({[3 (1H-tetrazol-1-yl)phenyl]oxy} acetyl) amino] benzoate, 3 [({[3 (1H-tetrazol-1-yl)phenyl]oxy} acetyl) amino] benzoic acid, N [3 (methyloxy)phenyl] 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N [4 (methyloxy)phenyl] 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N [2 chloro-5 (trifluoromethyl)phenyl] 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N [4 chloro-3 (trifluoromethyl)phenyl] 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N (4 aminophenyl) 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N (4 acetylphenyl) 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide.

34. (withdrawn from consideration, currently amended) A method of screening for modulators of c-Kit, the method comprising combining the compound according to claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-acetamide, N-[4 (phenyloxy)phenyl] . 2 -{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N (3,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy) acetamide, N (2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N (2,5 dimethylphenyl) 2 -{[3 (1H tetrazol 1yl)phenylloxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenylloxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl] - oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4 ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-acetamide, N-[2-(ethyloxy)-phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy) acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3methylphenyl) 2-{[3 (1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl) 2-{[3 (1H-tetrazol-1-yl)phenyl]oxy}acetamide, Ntetrazol-1-yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}

tetrazol 1-yl)phenyl]oxy} N [2 (trifluoro-methyl)phenyl] acetamide, 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} N-[3 (trifluoromethyl) phenyl] acetamide, methyl 4-{({[3 (1H-tetrazol 1-yl)phenyl]oxy} acetyl)amino} benzoate, ethyl 4-{({[3 (1H-tetrazol 1-yl)phenyl]oxy} acetyl)amino} benzoate, 3-{({[3 (1H-tetrazol 1-yl)phenyl]oxy} acetyl)amino} benzoic acid, N-[3 (methyloxy)phenyl] 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, N-[4 (methyloxy)phenyl] 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, N-[4-chloro-5-(trifluoromethyl)phenyl] 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl] 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, N-(4-acetylphenyl) 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, N-(4-acetylphenyl) 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl) 2-{[3 (1H-tetrazol 1-yl)phenyl]oxy} acetamide, and determining the effect of the candidate agent on c-Kit activity.

35. (withdrawn from consideration, currently amended) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising the compound according to claim 1 or a compound selected from N-naphthalen-1-yl-2 {[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N [4 (phenyloxy)phenyl] -2 -[[3 (1H-tetrazol-1yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N (3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-(2,4,6trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy}-acetamide, N-(4-ethylphenyl) 2-{[3 (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl) 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy} acetamide, N-[2 (ethyloxy) phenyl] 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl] 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-acetamide, N-[4-(dimethylamino)phenyl] 2 {[3 (1H-tetrazol-1-yl)phenyl]oxy}acetamide, N (2,3dichlorophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy} acetamide, N (4 chloro 3 methylphenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy} acetamide, N (4 bromophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N (4 fluorophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N (4 fluorophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N (4 fluorophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] N [2 (trifluoro methyl)phenyl] acetamide, 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] N [3 (trifluoromethyl) phenyl] acetamide, methyl 4 [([3 (1H tetrazol 1 yl)phenyl]oxy]acetyl)amino] benzoate, ethyl 4 [([3 (1H tetrazol 1 yl)phenyl]oxy]acetyl)amino] benzoate, 3 [([3 (1H tetrazol 1 yl)phenyl]oxy]acetyl)amino] benzoic acid, N [3 (methyloxy)phenyl] 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N [4 (methyloxy)phenyl] 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N [4 chloro 3 (trifluoromethyl)phenyl] 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N [4 chloro 3 (trifluoromethyl)phenyl] 2 [[3 (1H tetrazol 4 yl)phenyl]oxy] acetamide, N (4 chlorophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N (4 aminophenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, N (4 acetylphenyl) 2 [[3 (1H tetrazol 1 yl)phenyl]oxy] acetamide, to a cell or a plurality of cells.